查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2007864

數位療法平台市場預測至2034年—按產品類型、適應症、技術、應用、最終用戶和地區分類的全球分析

Digital Therapeutics Platforms Market Forecasts to 2034 - Global Analysis By Product Type, Indication, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球數位治療平台市場規模將達到 72 億美元，並在預測期內以 23.3% 的複合年成長率成長，到 2034 年將達到 385 億美元。

數位療法平台是指以軟體驅動的醫療干預措施，它透過行動應用程式、主導介面、穿戴式裝置整合以及包括虛擬實境在內的身臨其境型技術，為患者提供循證治療方案，幫助他們管理和預防臨床疾病。這些平台針對糖尿病、精神疾病、心血管疾病和物質使用障礙等疾病，旨在促進行為改變、疾病自我管理、復健支持和認知療法。它們可以單獨使用，也可以與藥物治療合併使用，並且需要在主要市場獲得監管部門的核准。

慢性病負擔加重

慢性病負擔日益加重是推動需求成長的主要因素，這主要是由於全球人口成長導致糖尿病、心血管疾病和精神疾病的盛行率不斷上升，需要持續的推動要素，而不僅僅是偶爾的門診就診。保險公司正在擴大數位療法的承保範圍，將其作為傳統藥物的一種經濟有效的補充，從而降低住院率並提高用藥依從性。此外，將數位療法整合到旨在支持員工心理健康的企業健康計畫中，也為平台開發人員創造了可觀的B2B收入來源。

還款方式不一致

各國醫療體系報銷流程的不一致嚴重限制了數位藥品市場的成長。私人保險公司、公共保險機構以及自費市場的碎片化保險政策，使得平台業者的收入難以預測。德國、日本、美國和英國在報銷臨床證據要求上的差異，導致了成本高昂的平行監管申請。醫生處方能力的不足進一步限制了病患的用藥途徑，並阻礙了保險公司建立標準化的保險覆蓋框架。

處方箋數位藥物的擴張

隨著德國、日本和美國的監管機構正式建立起由臨床醫生開立處方且醫保覆蓋的軟體醫療干預流程，僅憑處方箋的數位療法的擴張帶來了變革性的商業機會。德國數位醫療設備（DiGA）框架下的核准已樹立了支付先例，這將有助於在歐洲市場推廣類似的監管模式。與製藥業拓展聯合行銷夥伴關係，使數位療法開發商能夠利用現有的銷售網路和支付方關係，加速產品進入市場。

與患者參與和持續使用相關的風險

病患參與度和長期留存率的挑戰對數位治療平台的生存構成根本性的商業性威脅。這是因為臨床療效的驗證依賴持續使用，而許多平台難以在最初的推廣期後維持使用者使用。高流失率會削弱真實世界療效數據的生成，而這些數據對於與支付方進行報銷談判至關重要。此外，競爭性的健康應用和通用數位健康工具進一步分散了用戶興趣，使得差異化的臨床價值驗證對於平台的商業性永續性變得愈發重要。

新冠疫情的影響：

在疫情封鎖期間，患者尋求遠距疾病管理解決方案，這大大提高了人們對數位療法市場的認知度，並加速了支付方和醫療服務提供者對相關平台報銷的接受度。數位療法處方與遠端醫療的整合為混合醫療模式樹立了先例。疫情後，人們對行為醫學的需求持續推動數位心理健康療法的發展，而監管機構則優先考慮簡化數位醫療設備的核准流程。

在預測期內，遊戲療法領域預計將成為最大的細分市場。

鑑於遊戲化療法在患者參與度方面展現出優於傳統行為介入方式的優勢，尤其是在兒童不足過動症（ADHD）、認知復健和神經系統疾病的治療方面，預計在預測期內，遊戲化療法將佔據最大的市場佔有率。獲得FDA已通過核准的遊戲化療法平台已在商業性和臨床療效方面樹立了先例。與傳統數位介面相比，更高的患者依從性正在推動支付方接受並促使醫生開立已通過核准的遊戲化療法產品。

預計在預測期內，糖尿病管理細分市場將呈現最高的複合年成長率。

在預測期內，糖尿病管理領域預計將呈現最高的成長率，這主要受以下因素驅動：2型糖尿病在全球範圍內的高發生率、血糖控制不佳導致的醫療保健成本不斷上升，以及大量臨床證據表明，透過數位化療法進行生活方式干涉能夠有效改善健康狀況。持續血糖監測和行為指導平台的整合正在催生一種全新的互聯醫療產品類型。保險公司日益認知到數位化管理糖尿病患者群體所帶來的成本節約優勢，從而擴大了保險覆蓋範圍並增加了處方量。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。這主要得益於美國食品藥物管理局 (FDA) 為醫療軟體設備設立了全新的 (de novo) 和 510(k) 監管途徑，慢性病高發導致支付方興趣日益濃厚，以及創業投資投資對數位健康平台的強勁投入。總部位於美國的數位療法公司，包括 Pear Therapeutics 和 Akili Interactive Labs，率先推出了基於處方箋的商業模式。大規模醫療系統將相關技術納入雇主健康保險福利計畫並推行相關項目，也支撐了該地區龐大的市場需求。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於智慧型手機普及率的快速提升、平台接入基礎設施的完善、日本和韓國國家級數位醫療投資項目的擴大，以及中國和印度龐大的慢性疾病患者群體。亞太地區各國政府的數位醫療政策和國家級慢性病管理計畫正在加速醫療系統層面數位療法的應用，從而帶來顯著的市場規模成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章：全球數位治療平台市場：依產品類型分類

  • 以軟體為基礎的治療方法
  • 基於行動應用程式的治療方法
  • 網路為基礎的平台
  • 穿戴式整合治療設備
  • 遊戲治療方法
  • VR/AR治療
  • 其他產品類型

第6章 全球數位治療平台市場：依適應症分類

  • 糖尿病管理
  • 精神疾病
  • 心血管疾病
  • 呼吸系統疾病
  • 物質使用障礙
  • 神經系統疾病

第7章 全球數位治療平台市場：依技術分類

  • 人工智慧和機器學習
  • 雲端運算
  • 巨量資料分析
  • 物聯網整合
  • 區塊鏈用於資料安全
  • 預測分析

第8章 全球數位治療平台市場：按應用分類

  • 治療/管理
  • 預防醫學
  • 復原
  • 慢性病管理
  • 行為療法
  • 遠端監控
  • 其他用途

第9章 全球數位治療平台市場：依最終用戶分類

  • 病人
  • 醫療服務提供方
  • 付款人
  • 雇主
  • 製藥公司
  • 研究機構
  • 其他最終用戶

第10章：全球數位治療平台市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Pear Therapeutics
  • Omada Health
  • Livongo Health
  • Teladoc Health
  • Propeller Health
  • Akili Interactive Labs
  • Click Therapeutics
  • Better Therapeutics
  • Kaia Health
  • Noom Inc.
  • Happify Health
  • Voluntis
  • Biofourmis
  • WellDoc Inc.
  • DarioHealth Corp.
  • ResMed Inc.
  • Philips Healthcare
  • Medtronic plc
Product Code: SMRC34763

According to Stratistics MRC, the Global Digital Therapeutics Platforms Market is accounted for $7.2 billion in 2026 and is expected to reach $38.5 billion by 2034 growing at a CAGR of 23.3% during the forecast period. Digital therapeutics platforms refer to software-driven medical interventions that deliver evidence-based therapeutic functions to patients managing or preventing clinical conditions through mobile applications, web-based interfaces, wearable device integrations, and immersive technologies including virtual reality. These platforms target behavioral modification, disease self-management, rehabilitation support, and cognitive therapy across conditions including diabetes, mental health disorders, cardiovascular diseases, and substance use. They operate independently or adjunctively alongside pharmaceutical treatments and require regulatory clearance in major markets.

Market Dynamics:

Driver:

Chronic Disease Burden Growth

Chronic disease burden growth is a primary demand driver as global populations experience rising prevalence of diabetes, cardiovascular disease, and mental health disorders requiring continuous management beyond episodic clinical visits. Payer organizations are increasingly covering digital therapeutic prescriptions as cost-effective supplements to pharmaceutical treatment, reducing hospitalization rates and improving adherence outcomes. Employer wellness program adoption of digital therapeutics for workforce mental health support is additionally generating substantial B2B revenue streams for platform developers.

Restraint:

Reimbursement Pathway Inconsistency

Reimbursement pathway inconsistency across national healthcare systems materially constrains digital therapeutics market scaling, as fragmented coverage policies between commercial insurers, government payers, and self-pay market segments create uncertain revenue predictability for platform operators. Divergent clinical evidence requirements for reimbursement in Germany, Japan, the U.S., and the UK generate costly parallel regulatory submissions. Limited physician prescribing familiarity further reduces patient access and compounds payer reluctance to establish standard coverage frameworks.

Opportunity:

Prescription Digital Therapeutics Expansion

Prescription digital therapeutics expansion represents a transformative commercial opportunity as regulatory agencies in Germany, Japan, and the United States formalize pathways for clinician-prescribed, reimbursable software-based medical interventions. German DiGA framework approvals have established a payment precedent inspiring parallel regulatory models across European markets. Growing pharmaceutical industry co-commercialization partnerships are enabling digital therapeutic developers to leverage established sales force infrastructure and payer relationships for accelerated market access.

Threat:

Patient Engagement and Retention Risks

Patient engagement and long-term retention challenges represent a fundamental commercial threat to digital therapeutics platform viability, as clinical outcomes evidence depends on sustained usage that many platforms struggle to maintain beyond initial onboarding periods. High dropout rates undermine real-world effectiveness data generation critical for payer reimbursement negotiations. Competing wellness applications and generic digital health tools further fragment user attention, making differentiated clinical value demonstration increasingly essential for platform commercial sustainability.

Covid-19 Impact:

COVID-19 dramatically expanded digital therapeutics market awareness as patients sought remote disease management solutions during lockdown periods, accelerating payer and provider openness to platform reimbursement. Telehealth integration with digital therapeutic prescriptions created hybrid care model precedents. Post-pandemic behavioral healthcare demand has sustained digital mental health therapeutics growth, while regulatory agencies prioritized streamlined digital health device clearance frameworks.

The gaming-based therapeutics segment is expected to be the largest during the forecast period

The gaming-based therapeutics segment is expected to account for the largest market share during the forecast period, due to demonstrated engagement advantages over conventional behavioral intervention interfaces, particularly in pediatric ADHD, cognitive rehabilitation, and neurological condition management. FDA-cleared gaming-based therapeutic platforms have established commercial and clinical validation precedents. Strong patient adherence metrics relative to traditional digital interfaces have driven payer acceptance and physician prescribing adoption for approved gaming therapeutic products.

The diabetes management segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the diabetes management segment is predicted to witness the highest growth rate, driven by the global epidemic of Type 2 diabetes, escalating healthcare costs associated with poor glycemic control, and compelling clinical evidence for digital therapeutic lifestyle intervention effectiveness. Continuous glucose monitoring integration with behavioral coaching platforms is generating new connected care product categories. Payers are increasingly recognizing the cost savings from digitally managed diabetes populations, expanding coverage policies and driving prescription volume growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to established FDA de novo and 510(k) regulatory pathways for software medical devices, high chronic disease prevalence driving payer interest, and robust venture capital investment in digital health platforms. U.S.-based digital therapeutics companies including Pear Therapeutics and Akili Interactive Labs pioneered commercial prescription models. Employer health benefits integration and large health system adoption programs sustain dominant regional demand.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding smartphone penetration creating platform accessibility infrastructure, growing national digital health investment programs in Japan and South Korea, and vast chronic disease patient populations in China and India. Government digital health mandates and national chronic disease management programs across Asia Pacific markets are incentivizing digital therapeutic adoption at healthcare system level, generating substantial volume growth.

Key players in the market

Some of the key players in Digital Therapeutics Platforms Market include Pear Therapeutics, Omada Health, Livongo Health, Teladoc Health, Propeller Health, Akili Interactive Labs, Click Therapeutics, Better Therapeutics, Kaia Health, Noom Inc., Happify Health, Voluntis, Biofourmis, WellDoc Inc., DarioHealth Corp., ResMed Inc., Philips Healthcare, and Medtronic plc.

Key Developments:

In March 2026, Omada Health announced a major health plan partnership to deliver digital diabetes prevention and management programs across 2 million covered members.

In February 2026, ResMed Inc. expanded its digital therapeutic sleep management portfolio through acquisition of a behavioral insomnia therapy platform with FDA breakthrough status.

In January 2026, Akili Interactive Labs received expanded FDA clearance for its gaming-based cognitive therapy platform addressing adult ADHD beyond the initial pediatric indication approval.

Product Types Covered:

  • Software-based Therapeutics
  • Mobile App-based Therapeutics
  • Web-based Platforms
  • Wearable-integrated Therapeutics
  • Gaming-based Therapeutics
  • VR/AR Therapeutics
  • Other Product Types

Indications Covered:

  • Diabetes Management
  • Mental Health Disorders
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Substance Use Disorders
  • Neurological Disorders

Technologies Covered:

  • AI & Machine Learning
  • Cloud Computing
  • Big Data Analytics
  • IoT Integration
  • Blockchain for Data Security
  • Predictive Analytics

Applications Covered:

  • Treatment & Management
  • Preventive Care
  • Rehabilitation
  • Chronic Disease Management
  • Behavioral Therapy
  • Remote Monitoring
  • Other Applications

End Users Covered:

  • Patients
  • Healthcare Providers
  • Payers
  • Employers
  • Pharmaceutical Companies
  • Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-110 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Therapeutics Platforms Market, By Product Type

  • 5.1 Software-based Therapeutics
  • 5.2 Mobile App-based Therapeutics
  • 5.3 Web-based Platforms
  • 5.4 Wearable-integrated Therapeutics
  • 5.5 Gaming-based Therapeutics
  • 5.6 VR/AR Therapeutics
  • 5.7 Other Product Types

6 Global Digital Therapeutics Platforms Market, By Indication

  • 6.1 Diabetes Management
  • 6.2 Mental Health Disorders
  • 6.3 Cardiovascular Diseases
  • 6.4 Respiratory Diseases
  • 6.5 Substance Use Disorders
  • 6.6 Neurological Disorders

7 Global Digital Therapeutics Platforms Market, By Technology

  • 7.1 AI & Machine Learning
  • 7.2 Cloud Computing
  • 7.3 Big Data Analytics
  • 7.4 IoT Integration
  • 7.5 Blockchain for Data Security
  • 7.6 Predictive Analytics

8 Global Digital Therapeutics Platforms Market, By Application

  • 8.1 Treatment & Management
  • 8.2 Preventive Care
  • 8.3 Rehabilitation
  • 8.4 Chronic Disease Management
  • 8.5 Behavioral Therapy
  • 8.6 Remote Monitoring
  • 8.7 Other Applications

9 Global Digital Therapeutics Platforms Market, By End User

  • 9.1 Patients
  • 9.2 Healthcare Providers
  • 9.3 Payers
  • 9.4 Employers
  • 9.5 Pharmaceutical Companies
  • 9.6 Research Organizations
  • 9.7 Other End Users

10 Global Digital Therapeutics Platforms Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Pear Therapeutics
  • 13.2 Omada Health
  • 13.3 Livongo Health
  • 13.4 Teladoc Health
  • 13.5 Propeller Health
  • 13.6 Akili Interactive Labs
  • 13.7 Click Therapeutics
  • 13.8 Better Therapeutics
  • 13.9 Kaia Health
  • 13.10 Noom Inc.
  • 13.11 Happify Health
  • 13.12 Voluntis
  • 13.13 Biofourmis
  • 13.14 WellDoc Inc.
  • 13.15 DarioHealth Corp.
  • 13.16 ResMed Inc.
  • 13.17 Philips Healthcare
  • 13.18 Medtronic plc

List of Tables

  • Table 1 Global Digital Therapeutics Platforms Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Digital Therapeutics Platforms Market Outlook, By Product Type (2023-2034)($MN)
  • Table 3 Global Digital Therapeutics Platforms Market Outlook, By Software-based Therapeutics (2023-2034)($MN)
  • Table 4 Global Digital Therapeutics Platforms Market Outlook, By Mobile App-based Therapeutics (2023-2034)($MN)
  • Table 5 Global Digital Therapeutics Platforms Market Outlook, By Web-based Platforms (2023-2034)($MN)
  • Table 6 Global Digital Therapeutics Platforms Market Outlook, By Wearable-integrated Therapeutics (2023-2034)($MN)
  • Table 7 Global Digital Therapeutics Platforms Market Outlook, By Gaming-based Therapeutics (2023-2034)($MN)
  • Table 8 Global Digital Therapeutics Platforms Market Outlook, By VR/AR Therapeutics (2023-2034)($MN)
  • Table 9 Global Digital Therapeutics Platforms Market Outlook, By Other Product Types (2023-2034)($MN)
  • Table 10 Global Digital Therapeutics Platforms Market Outlook, By Indication (2023-2034)($MN)
  • Table 11 Global Digital Therapeutics Platforms Market Outlook, By Diabetes Management (2023-2034)($MN)
  • Table 12 Global Digital Therapeutics Platforms Market Outlook, By Mental Health Disorders (2023-2034)($MN)
  • Table 13 Global Digital Therapeutics Platforms Market Outlook, By Cardiovascular Diseases (2023-2034)($MN)
  • Table 14 Global Digital Therapeutics Platforms Market Outlook, By Respiratory Diseases (2023-2034)($MN)
  • Table 15 Global Digital Therapeutics Platforms Market Outlook, By Substance Use Disorders (2023-2034)($MN)
  • Table 16 Global Digital Therapeutics Platforms Market Outlook, By Neurological Disorders (2023-2034)($MN)
  • Table 17 Global Digital Therapeutics Platforms Market Outlook, By Technology (2023-2034)($MN)
  • Table 18 Global Digital Therapeutics Platforms Market Outlook, By AI & Machine Learning (2023-2034)($MN)
  • Table 19 Global Digital Therapeutics Platforms Market Outlook, By Cloud Computing (2023-2034)($MN)
  • Table 20 Global Digital Therapeutics Platforms Market Outlook, By Big Data Analytics (2023-2034)($MN)
  • Table 21 Global Digital Therapeutics Platforms Market Outlook, By IoT Integration (2023-2034)($MN)
  • Table 22 Global Digital Therapeutics Platforms Market Outlook, By Blockchain for Data Security (2023-2034)($MN)
  • Table 23 Global Digital Therapeutics Platforms Market Outlook, By Predictive Analytics (2023-2034)($MN)
  • Table 24 Global Digital Therapeutics Platforms Market Outlook, By Application (2023-2034)($MN)
  • Table 25 Global Digital Therapeutics Platforms Market Outlook, By Treatment & Management (2023-2034)($MN)
  • Table 26 Global Digital Therapeutics Platforms Market Outlook, By Preventive Care (2023-2034)($MN)
  • Table 27 Global Digital Therapeutics Platforms Market Outlook, By Rehabilitation (2023-2034)($MN)
  • Table 28 Global Digital Therapeutics Platforms Market Outlook, By Chronic Disease Management (2023-2034)($MN)
  • Table 29 Global Digital Therapeutics Platforms Market Outlook, By Behavioral Therapy (2023-2034)($MN)
  • Table 30 Global Digital Therapeutics Platforms Market Outlook, By Remote Monitoring (2023-2034)($MN)
  • Table 31 Global Digital Therapeutics Platforms Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 32 Global Digital Therapeutics Platforms Market Outlook, By End User (2023-2034)($MN)
  • Table 33 Global Digital Therapeutics Platforms Market Outlook, By Patients (2023-2034)($MN)
  • Table 34 Global Digital Therapeutics Platforms Market Outlook, By Healthcare Providers (2023-2034)($MN)
  • Table 35 Global Digital Therapeutics Platforms Market Outlook, By Payers (2023-2034)($MN)
  • Table 36 Global Digital Therapeutics Platforms Market Outlook, By Employers (2023-2034)($MN)
  • Table 37 Global Digital Therapeutics Platforms Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 38 Global Digital Therapeutics Platforms Market Outlook, By Research Organizations (2023-2034)($MN)
  • Table 39 Global Digital Therapeutics Platforms Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.